Top Page
Luye Pharma Group
(2186)
Luye Pharma Group (2186) vs. iShares MSCI Hong Kong ETF (EWH)
Luye Pharma Group Business Overview & Revenue Model
Luye Pharma Group Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.17B | 6.06B | 6.14B | 5.98B | 5.20B | 5.54B |
| Gross Profit | 4.12B | 4.04B | 4.20B | 4.14B | 3.40B | 3.99B |
| EBITDA | 1.73B | 1.79B | 2.08B | 1.81B | 906.88M | 1.88B |
| Net Income | 396.94M | 471.89M | 532.61M | 604.81M | -134.39M | 706.59M |
Balance Sheet | ||||||
| Total Assets | 32.03B | 29.61B | 25.49B | 24.25B | 22.58B | 20.63B |
| Cash, Cash Equivalents and Short-Term Investments | 8.83B | 6.50B | 6.11B | 5.54B | 5.51B | 5.41B |
| Total Debt | 11.87B | 10.32B | 8.42B | 9.10B | 9.49B | 9.98B |
| Total Liabilities | 15.49B | 13.86B | 11.96B | 13.21B | 13.47B | 12.53B |
| Stockholders Equity | 14.69B | 14.15B | 12.53B | 10.18B | 8.49B | 7.89B |
Cash Flow | ||||||
| Free Cash Flow | -31.91M | -1.54B | 430.23M | 490.14M | -1.36B | -486.43M |
| Operating Cash Flow | 562.16M | 167.76M | 1.60B | 1.65B | 182.37M | 1.03B |
| Investing Cash Flow | -965.94M | -1.47B | -1.42B | -1.66B | -3.44B | 138.20M |
| Financing Cash Flow | 1.98B | 2.96B | 841.60M | 54.15M | 1.88B | 253.98M |
Luye Pharma Group Technical Analysis
Luye Pharma Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$121.36B | 29.20 | 11.30% | 2.70% | -18.07% | -33.27% | |
72 Outperform | HK$14.61B | 13.77 | 25.92% | 3.93% | 19.05% | 13.68% | |
64 Neutral | HK$11.00B | 14.47 | 6.69% | 4.28% | -8.49% | -9.46% | |
58 Neutral | HK$11.31B | 25.00 | 2.85% | ― | -2.54% | -48.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$14.65B | -165.26 | -1.87% | 0.87% | 19.21% | -115.91% |
Luye Pharma Group Corporate Events
Luye Pharma Group has completed the transfer of a 25% equity interest in its subsidiary Nanjing Luye from an exiting investor to NJ Xinshi, a PRC limited partnership, for a consideration of RMB1.086 billion, effective 19 January 2026. Following the deal, Nanjing Luye is now owned 75% by Luye Pharma’s group and 25% by NJ Xinshi, with the price determined using a pre-agreed valuation formula from a prior investment agreement as an objective benchmark. The transaction, classified both as a discloseable and connected transaction under Hong Kong Listing Rules because the exiting investor was a substantial shareholder at the subsidiary level, has been approved by the board and deemed fair and reasonable by independent non-executive directors, allowing it to proceed under an announcement-only regime without requiring a circular, independent financial advice or shareholder approval. The introduction of NJ Xinshi as a new partner, under a partnership agreement involving Hangzhou Xinshi, Yantai Hexin, China Cinda and Shandong Luye, gives Luye Pharma greater influence over the identity and alignment of its minority partner in Nanjing Luye while providing an orderly exit for the previous investor.
The most recent analyst rating on (HK:2186) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
Luye Pharma Group has announced a RMB285 million capital injection into its subsidiary Nanjing Luye by Nanjing Xinan and Ningbo Cinda, which will leave the company ultimately controlled by Shenzhen Luye with a 70.01% stake, alongside minority holdings by NJ Xinshi, Nanjing Xinan and Ningbo Cinda. As part of the deal, Luye’s affiliate Yantai Luye has entered into equity option agreements granting it call options to buy out the new investors’ stakes and granting those investors put options to sell their interests under certain conditions, with Luye Pharma also providing a guarantee for Yantai Luye’s obligations; the structure amounts to a deemed partial disposal and a series of discloseable but non-shareholder-approved transactions under Hong Kong listing rules, underscoring the group’s use of flexible financing while retaining long-term control over its Nanjing platform.
The most recent analyst rating on (HK:2186) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
Luye Pharma Group has announced that China’s drug regulator has accepted a New Drug Application for a new indication of its Class 1 innovative drug Ruoxinlin (toludesvenlafaxine sustained-release tablets) to treat generalized anxiety disorder (GAD), building on its prior approval for major depressive disorder. Supported by positive Phase III data showing rapid and broad symptom relief, high response and remission rates, and a favorable safety profile compared with standard SSRIs and SNRIs, Ruoxinlin could become the first serotonin, norepinephrine and dopamine reuptake inhibitor approved for GAD in China, addressing a large, under-treated patient population and a market that has seen no Class 1 innovative anxiety drug approvals in two decades; if approved, the new use and existing reimbursement status are expected to deepen Ruoxinlin’s clinical penetration and strengthen Luye Pharma’s positioning in China’s CNS and mental health therapeutics market.
The most recent analyst rating on (HK:2186) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
Luye Pharma Group has appointed independent non-executive director Ms. Xia Lian as a member of its nomination committee, effective 31 December 2025, expanding the committee to four members. The updated composition, led by chairman Professor Lo Yuk Lam and including Mr. Zhang Hua Qiao, Mr. Choy Sze Chung Jojo and Ms. Xia, underscores the company’s emphasis on strengthened corporate governance and oversight of board appointments as it continues to operate in a highly regulated and competitive pharmaceutical market.
The most recent analyst rating on (HK:2186) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
Luye Pharma Group Ltd. has announced the current composition of its board of directors, comprising four executive directors, two non-executive directors and five independent non-executive directors, reflecting a diversified governance structure. The company has also detailed the membership and chairmanship of its four key board committees—Audit, Remuneration, Nomination and Environmental, Social and Governance—signalling an emphasis on structured oversight, regulatory compliance and ESG governance that may strengthen investor confidence and corporate transparency.
The most recent analyst rating on (HK:2186) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
Luye Pharma Group has updated the terms of reference for its Nomination Committee, originally adopted in 2014 and amended most recently on 31 December 2025, to refine governance around director appointments and Board composition. The revised framework formalizes the committee’s purpose of identifying, screening and recommending Board candidates, setting nomination guidelines, requiring a majority of independent non-executive directors on the committee, mandating at least one member of a different gender, and detailing procedures for meetings, access to management, resource support and annual self-evaluation, reinforcing the company’s corporate governance practices and oversight of Board succession.
The most recent analyst rating on (HK:2186) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
Luye Pharma Group has structured a series of transactions around the transfer of a 25% equity interest in its subsidiary Nanjing Luye for RMB1.086 billion to limited partnership NJ Xinshi, in which its unit Shandong Luye holds an approximately 33.2% stake alongside China Cinda and other general partners. To support and control this investment structure, related entities of Luye have agreed to multiple option arrangements, including a put option giving NJ Xinshi the right to require Yantai Luye to repurchase its stake in Nanjing Luye under certain conditions, a call option allowing Yantai Luye to acquire China Cinda’s interest in NJ Xinshi (and simultaneously that of Hangzhou Xinshi), and a corresponding put option enabling China Cinda to exit by selling its entire partnership interest to Yantai Luye. In addition, Yantai Luye must compensate China Cinda if NJ Xinshi cannot meet required semi-annual distributions, while Luye Pharma and Shenzhen Luye will jointly guarantee Yantai Luye’s obligations under the partnership option agreements and back a bank facility of up to RMB648 million to be obtained by NJ Xinshi after completion, underscoring Luye’s commitment to supporting the financing and risk management framework around the Nanjing Luye stake transfer.
The most recent analyst rating on (HK:2186) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
Luye Pharma Group has granted Jiangsu Nhwa Hexin Pharmaceutical Marketing, a subsidiary of CNS-focused specialist Jiangsu Nhwa Pharmaceutical, exclusive rights to commercialize three long-acting injectable antipsychotics—Rykindo, Ruibailai and Meibirui—in mainland China, all indicated for schizophrenia. Under the 10-year agreement, Luye retains product ownership, regulatory approvals, intellectual property and manufacturing responsibilities, while Nhwa will handle distribution and commercialization through its nationwide network of more than 10,000 hospitals and extensive presence in mental health and primary care institutions, in return for a one-off US$20 million licensing fee. The partnership aligns two leading CNS players to expand access to differentiated long-acting schizophrenia treatments, particularly at the community and primary-care level, supporting better adherence and relapse prevention in a market of around 8 million patients, and is expected to accelerate value creation from Luye’s CNS pipeline and reinforce both companies’ positioning in China’s rapidly developing CNS therapeutics segment.
The most recent analyst rating on (HK:2186) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
Luye Pharma Group has completed the issuance of 1,500,000 Exchangeable Preference Shares through its wholly-owned subsidiary, Luye Geneora Holding Limited. These shares are exchangeable into existing shares of Boan Biotech, representing approximately 16.15% of Boan Biotech’s issued shares. This strategic financial move, involving investment from Bluebell Asset Holding Ltd., aims to strengthen Luye Pharma’s position in the biotech sector without diluting Boan Biotech’s current shareholding structure.
The most recent analyst rating on (HK:2186) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
Luye Pharma Group Ltd. announced the inclusion of five new products in China’s 2025 National Reimbursement Drug List and Commercial Insurance Innovative Drug List, enhancing its market presence. This inclusion marks a significant milestone for the company, as it positions its products, such as Mimeixin® and Ruibailai®, for broader access and potential growth in the Chinese market, addressing critical needs in pain management and schizophrenia treatment.
The most recent analyst rating on (HK:2186) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
Luye Pharma Group Ltd. has received FDA clearance to initiate clinical trials in the U.S. for its new drug LY03017, designed to treat Alzheimer’s disease psychosis, Parkinson’s disease psychosis, and negative symptoms of schizophrenia. This development highlights the company’s strategic focus on CNS diseases and its commitment to addressing unmet medical needs in these areas, potentially enhancing its market position and offering new treatment options for patients globally.
The most recent analyst rating on (HK:2186) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
Luye Pharma Group announced the issuance of exchangeable preference shares by its wholly-owned subsidiary, which involves a subscription agreement with a third-party subscriber for USD150 million. This transaction will result in a reduction of Luye Pharma’s shareholding in Boan Biotech, potentially affecting its control over the subsidiary and constituting a discloseable transaction under Hong Kong’s listing rules.
The most recent analyst rating on (HK:2186) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.